Kim Lab @ Hanyang - Publications

Publications

1. Cho AH, Cho SY, Kim S, Lee S. Targeting emerging viruses with phage display-driven engineered antibodies: Bridging molecular design and clinical application. Mol Aspects Med 2026; 107:101441

2. Kim S, Travisano KA, Wilder B, Palomares M, Zheng C, Seaman MS, Kim PS. Exceptionally broad HIV-1 neutralization via bispecific antibody-mediated prepositioning. Proc Natl Acad Sci USA 2025; 122(40): e2517311122

3. Filsinger Interrante M, Tang S, Kim S, Shanker V, Hie B, Bruun T, et al. Utilizing machine learning to improve neutralization potency of an HIV-1 antibody targeting the gp41 N-heptad repeat. ACS Chem Biol 2025; 20(7):1470-1480

4. Kim S, Radford CE, Xu D, Zhong J, Do J, Pham DM, et al. A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning. Nat Commun 2025; 16: 4617

5. Chang S*, Kim S*, Lee D, Lee SA, Chung J, Kwon S, Kim J. Laser-assisted recovery of on-chip phage viral DNA for phage fluorescence immunoassay microchip. BioChip J 2023; 17:431-438

6. Kim S, Filsinger Interrante MV, Kim PS. Enhancing HIV-1 neutralization by increasing the local concentration of membrane-proximal external region-directed broadly neutralizing antibodies. J Virol 2023; 97(1):e01647-22

7. Lee SJ*, Kim S*, Jo DH, Cho CS, Kim SR, Kang D, et al. Specific ablation of PDGFRb-overexpressing pericytes with antibody-drug conjugate potently inhibits pathological ocular neovascularization in mouse models. Commun Med (Lond) 2021;1:58

8. Chang S*, Kim S*, Han J, Ha S, Lee H, Song SW, et al. A high-throughput single-clone phage fluoresence microwell immunoassay and laser-driven clonal retrieval system. Biomolecules 2020; 10(4):517

9. Yoo DK, Lee SR, Jung Y, Han H, Lee HK, Han J, Kim S, Chae J, Ryu T, Chung J. Machine learning-guided prediction of antigen-reactive in silico clonotypes based on changes in clonal abundance through biopanning. Biomolecules 2020; 10(3):421

10. Shin JW, Kim S, Ha S, Choi B, Kim S, Im SA, Yoon TY, Chung J. The HER2 S310F mutant can form an active heterodimer with the EGFR, which can be inhibited by cetuximab but not by trastuzumab as well as pertuzumab. Biomolecules 2019; 9(10):E629

11. Noh J, Kim O, Jung Y, Han H, Kim JE, Kim S, Lee S, Park J, Jung RH, Kim SI, Park J, Han J, Lee H, Yoo DK, Lee AC, Kwon E, Ryu T, Chung J, Kwon S. High-throughput retrieval of physical DNA for NGS-identifiable clones in phage display library. MAbs 2019; 11(3):532-545

12. Kim S*, Lee H*, Noh J, Lee Y, Han H, Yoo DK, Kim H, Kwon S, Chung J. Efficient selection of antibodies reactive to homologous epitopes on human and mouse hepatocyte growth factors by Next-Generation Sequencing-based analysis of the B cell repertoire. Int J Mol Sci 2019; 20(2):E417

13. Kim S, Kim H, Jo DH, Kim JH, Kim SR, Kang D, Hwang D, Chung J. Bispecific anti-mPDGFRβ x cotinine scFv-Cκ-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFRβ expressing cells. Methods 2019; 154:125-135

14. Jin J, Park G, Park JB, Kim S, Kim H, Chung J. An Anti-EGFR x cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations. Exp Mol Med 2018; 50(5):67

15. Yang W, Yoon A, Lee S, Kim S, Han J, Chung J. Next-generation sequencing enables the discovery of more diverse positive clones from a phage-displayed antibody library. Exp Mol Med 2017; 49(3):e308

16. Choi H, Kim HJ, Kim J, Kim S, Yang J, Lee W, Park Y, Hyeon SJ, Lee DS, Ryu H, Chung J, Mook-Jung I. Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of Aβ-induced impaired axonal transport. Mol Neurodegener 2017; 12(1):23

17. Hwang D, Yoon A, Kim S, Kim H, Chung J. Establishment of a mammalian expression system for recombinant [-2]proPSA and a specific antibody against the truncated leader peptide. Biotechnol Appl Biochem 2017; 64(3):327-336

18. Yoon A, Shin JW, Kim S, Kim H, Chung J. Chicken scFvs with an artificial cysteine for site-directed conjugation. PLoS One 2016; 11(1):e0146907

*These authors contributed equally to this work

Intellectual properties

Development of a potent, broadly neutralizing bispecific antibody against HIV-1 (Provisional 63/869,990, 2025)
Engineered antibody constant region polypeptides and related methods (PCT/US2025/056200)
Anti-cntn4 antibody and use thereof (WO2022216014A1, US20240182563A1, EP4321535A1, JP2024514109A, CN117157324A, KR102291725B1)
Antibody against PDGF receptor beta and use thereof (PCT/KR2019/013122, WO2020071881A1, KR1020200039604, CA3115039, AU2019352482, BR112021006352, CN113166249, EP3868781, US20210371536, JP2022502457)
A novel antibody drug conjugate platform using a bispecific antibody and its use (PCT/KR2017/006552, WO2017222310A1, CN109414509, KR1020190023084, EP3473274, US20190328894, JP20191522653)
Chimeric antigen receptor cytotoxic cells displaying cotinine antibody and its use (PCT/KR2016/009047, WO2017030370A1, KR1020180031727, EP3339320, US20180256744, CN108463469, JP2018523487)

Technology transfers

Chung J, Kim S, Jin J, Chae J, “Anti-CNTN4 antibody and use thereof” (2021)-advanced to phase 1 clinical trial (NCT06235541) and is licensed to a global pharma
Choi K, Park H, Lee JE, Oh Y, Kim K, Kim S, Kim H, Chung J, “Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof” (2018)
Chung J, Kim H, Jin J, Park G, Kim S, “A novel antibody drug conjugate platform using a bispecific antibody and its use” (2018)